Front Biosci 2013, 5:204–213. 29. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP: Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999, 99(3):323–334.PubMedCrossRef 30. Chu EC, Tarnawski AS: PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit 2004, 10:RA235–RA241.PubMed 31. Temozolomide purchase Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald
W, Cordon-Cardo C, Pandolfi PP: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725–730.PubMedCentralPubMedCrossRef 32. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL: Detection of elevated levels of tumour associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672–675.PubMedCrossRef 33. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu
S: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 2010, 5:e13735.PubMedCentralPubMedCrossRef eFT508 chemical structure 34. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010, 28:1721–1726.PubMedCrossRef
35. Mahn R, see more Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J: Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011, 77:1265.PubMed 36. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel G, von Ruecker A, Müller SC, Ellinger J: MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 2011, 6:e25787.PubMedCentralPubMedCrossRef 37. Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Müller SC, Ellinger J: Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol 2012, doi:10.1007/s00345-012-1010-2. 38. Adam L, Wszolek MF, Liu CG, Jing W, Diao L, Zien A, Zhang L-gulonolactone oxidase JD, Jackson D, Dinney CP: Plasma microRNA profiles for bladder cancer detection. Urol Oncol 2013, 31:1701–1708.PubMedCrossRef 39. Lin Q, Chen T, Lin Q, Lin G, Lin J, Chen G, Guo L: Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J Surg Oncol 2013, 107:767–771.PubMedCrossRef 40. Kosaka N, Iguchi H, Ochiya T: Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010, 101:2087–2092.PubMedCrossRef 41. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA: MicroRNAs in body fluids the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011, 8:467–477.PubMedCentralPubMedCrossRef 42.